BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival

Katia Borgia Barbosa Pagnano, Israel Bendit, Carla Boquimpani, Carmino Antonio De Souza, Eliana C.M. Miranda, Ilana Zalcberg, Irene Larripa, Luciana Nardinelli, Rosana Antunes Silveira, Laura Fogliatto, Nelson Spector, Vaneuza Funke, Ricardo Pasquini, Vania Hungria, Carlos Sérgio Chiattone, Nelma Clementino, Monika Conchon, Elena Beatriz Moiraghi, Jose Luis Lopez, Carolina PavlovskyMiguel A. Pavlovsky, Eduardo E. Cervera, Luis Antonio Meillon, Belinda Simões, Nelson Hamerschlak, Alicia Helena Magarinos Bozzano, Ernesto Mayta, Jorge Cortes, Raquel M. Bengió

Research output: Contribution to journalArticle

Abstract

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

Original languageEnglish (US)
Pages (from-to)451-458
Number of pages8
JournalCancer Investigation
Volume33
Issue number9
DOIs
StatePublished - Oct 21 2015
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Mutation
Survival

Keywords

  • BCR-ABL mutations
  • Chronic myeloid leukemia
  • Imatinib
  • Resistance
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pagnano, K. B. B., Bendit, I., Boquimpani, C., De Souza, C. A., Miranda, E. C. M., Zalcberg, I., ... Bengió, R. M. (2015). BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Investigation, 33(9), 451-458. https://doi.org/10.3109/07357907.2015.1065499

BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival. / Pagnano, Katia Borgia Barbosa; Bendit, Israel; Boquimpani, Carla; De Souza, Carmino Antonio; Miranda, Eliana C.M.; Zalcberg, Ilana; Larripa, Irene; Nardinelli, Luciana; Silveira, Rosana Antunes; Fogliatto, Laura; Spector, Nelson; Funke, Vaneuza; Pasquini, Ricardo; Hungria, Vania; Chiattone, Carlos Sérgio; Clementino, Nelma; Conchon, Monika; Moiraghi, Elena Beatriz; Lopez, Jose Luis; Pavlovsky, Carolina; Pavlovsky, Miguel A.; Cervera, Eduardo E.; Meillon, Luis Antonio; Simões, Belinda; Hamerschlak, Nelson; Bozzano, Alicia Helena Magarinos; Mayta, Ernesto; Cortes, Jorge; Bengió, Raquel M.

In: Cancer Investigation, Vol. 33, No. 9, 21.10.2015, p. 451-458.

Research output: Contribution to journalArticle

Pagnano, KBB, Bendit, I, Boquimpani, C, De Souza, CA, Miranda, ECM, Zalcberg, I, Larripa, I, Nardinelli, L, Silveira, RA, Fogliatto, L, Spector, N, Funke, V, Pasquini, R, Hungria, V, Chiattone, CS, Clementino, N, Conchon, M, Moiraghi, EB, Lopez, JL, Pavlovsky, C, Pavlovsky, MA, Cervera, EE, Meillon, LA, Simões, B, Hamerschlak, N, Bozzano, AHM, Mayta, E, Cortes, J & Bengió, RM 2015, 'BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival', Cancer Investigation, vol. 33, no. 9, pp. 451-458. https://doi.org/10.3109/07357907.2015.1065499
Pagnano, Katia Borgia Barbosa ; Bendit, Israel ; Boquimpani, Carla ; De Souza, Carmino Antonio ; Miranda, Eliana C.M. ; Zalcberg, Ilana ; Larripa, Irene ; Nardinelli, Luciana ; Silveira, Rosana Antunes ; Fogliatto, Laura ; Spector, Nelson ; Funke, Vaneuza ; Pasquini, Ricardo ; Hungria, Vania ; Chiattone, Carlos Sérgio ; Clementino, Nelma ; Conchon, Monika ; Moiraghi, Elena Beatriz ; Lopez, Jose Luis ; Pavlovsky, Carolina ; Pavlovsky, Miguel A. ; Cervera, Eduardo E. ; Meillon, Luis Antonio ; Simões, Belinda ; Hamerschlak, Nelson ; Bozzano, Alicia Helena Magarinos ; Mayta, Ernesto ; Cortes, Jorge ; Bengió, Raquel M. / BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival. In: Cancer Investigation. 2015 ; Vol. 33, No. 9. pp. 451-458.
@article{d0de089d0d9540c9930b70fb532b9bab,
title = "BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival",
abstract = "This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41{\%}) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16{\%}). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43{\%} vs. 65{\%}, p = 0.07 and 47{\%} vs. 72{\%}, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50{\%} vs. 39{\%} p = 0.01; PFS: 48{\%} vs. 30{\%} p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.",
keywords = "BCR-ABL mutations, Chronic myeloid leukemia, Imatinib, Resistance, Tyrosine kinase inhibitors",
author = "Pagnano, {Katia Borgia Barbosa} and Israel Bendit and Carla Boquimpani and {De Souza}, {Carmino Antonio} and Miranda, {Eliana C.M.} and Ilana Zalcberg and Irene Larripa and Luciana Nardinelli and Silveira, {Rosana Antunes} and Laura Fogliatto and Nelson Spector and Vaneuza Funke and Ricardo Pasquini and Vania Hungria and Chiattone, {Carlos S{\'e}rgio} and Nelma Clementino and Monika Conchon and Moiraghi, {Elena Beatriz} and Lopez, {Jose Luis} and Carolina Pavlovsky and Pavlovsky, {Miguel A.} and Cervera, {Eduardo E.} and Meillon, {Luis Antonio} and Belinda Sim{\~o}es and Nelson Hamerschlak and Bozzano, {Alicia Helena Magarinos} and Ernesto Mayta and Jorge Cortes and Bengi{\'o}, {Raquel M.}",
year = "2015",
month = "10",
day = "21",
doi = "10.3109/07357907.2015.1065499",
language = "English (US)",
volume = "33",
pages = "451--458",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival

AU - Pagnano, Katia Borgia Barbosa

AU - Bendit, Israel

AU - Boquimpani, Carla

AU - De Souza, Carmino Antonio

AU - Miranda, Eliana C.M.

AU - Zalcberg, Ilana

AU - Larripa, Irene

AU - Nardinelli, Luciana

AU - Silveira, Rosana Antunes

AU - Fogliatto, Laura

AU - Spector, Nelson

AU - Funke, Vaneuza

AU - Pasquini, Ricardo

AU - Hungria, Vania

AU - Chiattone, Carlos Sérgio

AU - Clementino, Nelma

AU - Conchon, Monika

AU - Moiraghi, Elena Beatriz

AU - Lopez, Jose Luis

AU - Pavlovsky, Carolina

AU - Pavlovsky, Miguel A.

AU - Cervera, Eduardo E.

AU - Meillon, Luis Antonio

AU - Simões, Belinda

AU - Hamerschlak, Nelson

AU - Bozzano, Alicia Helena Magarinos

AU - Mayta, Ernesto

AU - Cortes, Jorge

AU - Bengió, Raquel M.

PY - 2015/10/21

Y1 - 2015/10/21

N2 - This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

AB - This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

KW - BCR-ABL mutations

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Resistance

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84945468891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945468891&partnerID=8YFLogxK

U2 - 10.3109/07357907.2015.1065499

DO - 10.3109/07357907.2015.1065499

M3 - Article

C2 - 26288116

AN - SCOPUS:84945468891

VL - 33

SP - 451

EP - 458

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -